Foamix Pharmaceuticals Announces Publication of Abstract on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting

REHOVOT, Israel and BRIDGEWATER, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX ), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that its drug candidate FDX-104, for the treatment of skin toxicity due to Epidermal Growth Factor Receptor Inhibitors (EGFRI), will be featured in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, on Monday June 6, 2016 in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org .

In the poster entitled “ Safety and Activity of Topical 4% Doxycycline Foam (FDX-104) in Epidermal Growth Factor Receptor Inhibitor (EGFRI) Induced Skin Toxicity ,” the authors highlighted data from a Phase 2 randomized, double-blind, multicenter study investigating the safety and efficacy of self-applied, twice-daily, FDX-104 in 24 patients receiving cetuximab (Erbitux ® , Eli Lilly) or panitumumab (Vectibix ® , Amgen) for metastatic colon cancer. 

Acneiform rash is a common treatment-limiting side effect of antibody and small molecule EGFRIs used to treat various cancers. Absent an approved product, off-label oral doxycycline, a tetracycline analog, has been used with various degrees of success to prevent the rash. Oral doxycycline, however, may also cause limiting systemic side effects.

Foamix conducted a Phase 2, randomized, double-blind, multicenter study investigating the safety and efficacy of self-applied, twice-daily, FDX-104 in 24 patients receiving cetuximab or panitumumab for metastatic colon cancer. Each patient acted as her/his own control by applying FDX-104 to one side of the face and matching foam vehicle (placebo) to the other side, beginning one week prior to starting treatment with the EGFRI. Patients were evaluated until 4 weeks after EGFRI initiation. Rash was quantified by an independent blinded dermatologist using a Global Rash Severity (GSS) scale and by study investigators using a modified MASCC EGFRI Skin Toxicity Tool (MESTT). Maximum-grade rash severity on each side of the face at any visit was used in all analyses.

Foamix previously announced results showing that the overall difference in GSS grade 3 rash favored the FDX-104 treatment side. The comparison of a ranked difference between the two treatments, based on clinical importance, reached statistical significance (p=0.047, Wilcoxon Signed-Rank test) in favor of FDX104 over vehicle for the prevention of severe rash. Grade 3 rash developed in 9 patients (37.5%) on the placebo side, compared with only 4 patients (16.7%) on the FDX-104 side. Four patients had a 2-grade difference in GSS scoring (severe vs. mild) between sides. FDX104 applied to skin was well tolerated and safe, and caused no systemic side effects.

The time from EGFRI treatment initiation to first grade 3 rash trended in favor of FDX104 (hazard ratio = 0.2; p =0.096), as did the probability of remaining free of severe rash over time ( p =0.096). MESTT-based analyses had similar but nonstatistically significant results.

“We are very pleased to have the results of this Phase 2 study on FDX 104 accepted for ASCO this year," stated Dov Tamarkin, Ph.D., Foamix’s CEO. “There is a significant unmet need for a safe and effective treatment for EGFRI-induced rash, which is the most noticeable side effect of the EGFRI class of drugs. FDX104 has the potential to improve patients’ quality of life and help maintain patients on their optimal anti-cancer treatment.”

ASCO Poster Details  
Abstract Title: Safety and Activity of Topical 4% Doxycycline Foam (FDX104) in Epidermal Growth Factor Receptor Inhibitor (EGFRI) Induced Skin Toxicity
Abstract #: 10130
Session Title: Patient and Survivor Care
Poster Hall Location: Hall A, Poster Session (Board #118)
Presentation Time: Monday June 6, 1:00 PM to 4:30 PM (Central Time)

About Foamix Pharmaceuticals

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. The Company’s clinical stage product candidates include FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne, now in Phase 3 clinical studies, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea, and FDX-104, a doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs. In addition, Foamix has development and license agreements relating to its technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.

For more information, please visit www.foamixpharma.com .

Forward Looking Statements This press release may include forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations. Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors including, but not limited to, unexpected delays, excess costs or unfavorable results of clinical trials, delays or denial in the U.S. FDA approval process, additional competition in the acne market, denial of reimbursement by third party payors or inability to raise additional capital. We discuss many of these risks in greater detail under the heading “Risk Factors” in our most recent Annual Report on Form 20-F (File No. 161477078) filed on March 7, 2016, and elsewhere in that Annual Report. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Erbitux ® is a registered trademark of Eli Lilly & Co. Vectibix ® is a registered trademark of Amgen Inc.

Contact: Dorit Hayon Foamix Pharmaceuticals Ltd. +972-8-9316233 BD@foamixpharma.com US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 mrice@lifesciadvisors.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 379

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 382

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 344

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 15

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 160

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 59

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 58

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 88

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 358

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

The GEO Group Expands Services with $70 Million Investment

Updated Category News Views 182

The GEO Group's Major Investment in Service Expansion The GEO Group, Inc. (NYSE: GEO) has made headlines with its recent announcement of a substantial $70 million investment aimed at enhancing its capabilities in providing services to U.S. Immigration and Customs Enforcement (ICE). As the leading service provider for ICE, GEO currently manages approximately 21,000...

Continue Reading
NJ's $21.3M Water Fix Fights PFAS, Boosts AWK

Updated Category News Views 216

Water Woes Culminate in Triumph Alright, folks, you don't often see New Jersey in the headlines for anything groundbreaking in the right way, but here we are. The big news is a hefty $21.3 million project completion that finally puts some ammo against the notorious PFAS chemicals. If you've got any skin in the utility game or just a stake in clean water, this one's been...

Continue Reading
Volkswagen's CEO Calls for Major Union Concessions Amid Challenges

Updated Category News Views 69

Volkswagen Prepares for Union Negotiations Amid Growing Tensions Volkswagen, a major player in the automotive industry, is gearing up for important negotiations with labor unions. These talks are taking place as the company faces rising tensions and significant challenges within the industry. The CEO, Oliver Blume, anticipates that unions will propose measures focused on...

Continue Reading
Exploring the Growth of CAE Market and Key Players in 2025

Updated Category News Views 248

Overview of the Computer-Aided Engineering (CAE) Market The Computer-aided Engineering (CAE) market is experiencing significant growth, projected to reach approximately USD 19.96 billion by 2030. This remarkable rise is spurred on by a compound annual growth rate (CAGR) of 10.2% from its previous valuation of USD 12.28 billion. Driving Forces Behind Market Growth A major...

Continue Reading
Investors of RCI Hospitality Holdings Urged to Act Now

Updated Category News Views 201

Investors Alert for RCI Hospitality Holdings, Inc. Attention all investors in RCI Hospitality Holdings, Inc. (NASDAQ: RICK)! Recent developments concerning the company have raised significant concerns, particularly for shareholders who may have suffered financial losses. A class action lawsuit has been initiated and it’s essential for affected investors to be aware of...

Continue Reading